Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million on September 22, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 CNY | +4.91% | +2.62% | -17.25% |
Apr. 15 | Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 15 | Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023 | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.25% | 1.6B | |
+14.78% | 79.51B | |
+6.49% | 50.22B | |
+1.35% | 48.11B | |
+9.53% | 42.2B | |
+6.55% | 39.71B | |
+19.34% | 37.78B | |
+2.84% | 30.07B | |
-7.77% | 27.56B | |
-18.42% | 24.71B |
- Stock Market
- Equities
- 000627 Stock
- News Hubei Biocause Pharmaceutical Co., Ltd.
- Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.